Genetic and proteomic approaches to identify cancer drug targets

British Journal of Cancer

Volumn 106, Issue 2, 2012, Pages 254-261

  Roti, G ^a   Stegmaier, K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

cancer drug targets; chemical genomics; chemical proteomics; drug discovery; protein target identification; small molecule library screening

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AP 1497; AP 1780; CICLOPIROX; DEFEROXAMINE; DOXORUBICIN; ELONGATION FACTOR 1ALPHA; IMATINIB; IMMUNOPHILIN; INITIATION FACTOR 4A; K 252A; LANPERISONE; MOLSIDOMINE; PHOSPHOTRANSFERASE INHIBITOR; R 0317549; RAPAMYCIN; RESVERATROL; SHORT HAIRPIN RNA; TACROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENETIC SCREENING; GENOMICS; HUMAN; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEOMICS; REVIEW;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION; HUMANS; NEOPLASMS; PROTEOMICS;

EID: 84856415793     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.543     Document Type: Review

References (45)

1. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V, Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse U, Neubauer G, Ramsden N, Rick J, Kuster B, Drewes G (2007a) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035-1044 (Pubitemid 47517638)
2. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B (2007b) Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 389: 1017-1031 (Pubitemid 47482251)
3. Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N, Morse E, Lin K, Shen JP, Kwiatkowski NP, Gheldof N, Dekker J, DeAngelo DJ, Carr SA, Schreiber SL, Golub TR, Ebert BL (2010) Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci USA 107: 12617-12622
4. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 105: 9053-9058
5. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502
6. Carpenter AE (2007) Image-based chemical screening. Nat Chem Biol 3: 461-465 (Pubitemid 47080372)
7. Coombs GS, Schmitt AA, Canning CA, Alok A, Low IC, Banerjee N, Kaur S, Utomo V, Jones CM, Pervaiz S, Toone EJ, Virshup DM (2011) Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene; e-pub ahead of print 13 June 2011; doi:10.1038/onc.2011.228
8. Corsello SM, Roti G, Ross KN, Chow KT, Galinsky I, DeAngelo DJ, Stone RM, Kung AL, Golub TR, Stegmaier K (2009) Identification of AML1-ETO modulators by chemical genomics. Blood 113: 6193-6205
9. Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, Jaramillo DF, Chu AM, Jordan MI, Arkin AP, Davis RW (2004) Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci USA 101: 793-798 (Pubitemid 38121037)
10. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, Astromoff A, Davis RW (1999) Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet 21: 278-283 (Pubitemid 29124934)
11. Giuliano KA, Haskins JR, Taylor DL (2003) Advances in high content screening for drug discovery. Assay Drug Dev Technol 1: 565-577
12. Giuliano KA, DL, Dunlay RT, Gough A, Volosky JM, Zock J, Pavlakis GN, Taylor DL (1997) High-content screening: a new approach to easing key bottlenecks in the drug discovery process. J Biomol Screen 2: 249-259 (Pubitemid 127690015)
13. Gullbo J, Fryknas M, Rickardson L, Darcy P, Hagg M, Wickstrom M, Hassan S, Westman G, Brnjic S, Nygren P, Linder S, Larsson R (2011) Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment. Biochem Pharmacol 82: 139-147
14. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110: 4427-4435 (Pubitemid 351377809)
15. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17: 994-999 (Pubitemid 29474856)
16. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100: 4389-4394 (Pubitemid 36457739)
17. Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, Carr SA, Golub TR, Kung AL, Stegmaier K (2009) Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16: 281-294
18. Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT (2008) Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 111: 5654-5662
19. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT (2010) Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 116: 5983-5990
20. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10: 321-330 (Pubitemid 44512193)
21. Hoon S, Smith AM, Wallace IM, Suresh S, Miranda M, Fung E, Proctor M, Shokat KM, Zhang C, Davis RW, Giaever G, St Onge RP, Nislow C (2008) An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol 4: 498-506
22. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51 (Pubitemid 47026733)
23. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, Stepaniants SB, Shoemaker DD, Gachotte D, Chakraburtty K, Simon J, Bard M, Friend SH (2000) Functional discovery via a compendium of expression profiles. Cell 102: 109-126
24. Koehler AN, Shamji AF, Schreiber SL (2003) Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversityoriented synthesis. J Am Chem Soc 125: 8420-8421 (Pubitemid 36858396)
25. Kuruvilla FG, Shamji AF, Sternson SM, Hergenrother PJ, Schreiber SL (2002) Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 416: 653-657 (Pubitemid 34406768)
26. Lamb J (2007) The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7: 54-60 (Pubitemid 46020847)
27. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935 (Pubitemid 44497995)
28. Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA (2008) Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol 35: 401-409
29. Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, Wang J, Wu RP, Gomez F, Loo JA, Wohlschlegel JA, Vondriska TM, Pelletier J, Herschman HR, Clardy J, Clarke CF, Huang J (2009) Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci USA 106: 21984-21989
30. Luesch H, Chanda SK, Raya RM, DeJesus PD, Orth AP, Walker JR, Izpisua Belmonte JC, Schultz PG (2006) A functional genomics approach to the mode of action of apratoxin A. Nat Chem Biol 2: 158-167 (Pubitemid 44323868)
31. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, Garrett-Engele P, Rush CM, Bard M, Schimmack G, Phillips JW, Roberts CJ, Shoemaker DD (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116: 121-137 (Pubitemid 38156189)
32. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1: 376-386
33. Ong SE, Schenone M, Margolin AA, Li X, Do K, Doud MK, Mani DR, Kuai L, Wang X, Wood JL, Tolliday NJ, Koehler AN, Marcaurelle LA, Golub TR, Gould RJ, Schreiber SL, Carr SA (2009) Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci USA 106: 4617-4622
34. Palchaudhuri R, Hergenrother PJ (2011) Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. ACS Chem Biol 6: 21-33
35. Peck D, Crawford ED, Ross KN, Stegmaier K, Golub TR, Lamb J (2006) A method for high-throughput gene expression signature analysis. Genome Biol 7: R61
36. Rix U, Superti-Furga G (2009) Target profiling of small molecules by chemical proteomics. Nat Chem Biol 5: 616-624
37. Sanz MA (2006) Treatment of acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 147-155
38. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N, Jacks T (2011) Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci USA 108: 8773-8778
39. Stanton BZ, Peng LF, Maloof N, Nakai K, Wang X, Duffner JL, Taveras KM, Hyman JM, Lee SW, Koehler AN, Chen JK, Fox JL, Mandinova A, Schreiber SL (2009) A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol 5: 154-156
40. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR (2005) Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106: 2841-2848 (Pubitemid 41510762)
41. Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR (2004) Gene expression-based high-throughput screening( GE-HTS) and application to leukemia differentiation. Nat Genet 36: 257-263 (Pubitemid 38282750)
42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550 (Pubitemid 41528093)
43. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, Golub TR, Mootha VK (2008) Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 26: 343-351 (Pubitemid 351355127)
44. Wang X, Imber BS, Schreiber SL (2008) Small-molecule reagents for cellular pull-down experiments. Bioconjug Chem 19: 585-587 (Pubitemid 351431387)
45. West GM, Tucker CL, Xu T, Park SK, Han X, Yates 3rd JR, Fitzgerald MC (2010) Quantitative proteomics approach for identifying protein-drug interactions in complex mixtures using protein stability measurements. Proc Natl Acad Sci USA 107: 9078-9082